Biomark Diagnostics Inc. BMKDF
0.32 USD -0.01 (-4.08%)
At closeNov 9, 2026, 4:00 PM EST
0.3221 Day range 0.3221
0.2259 52-week range 0.5044
- YTD
- -6.07%
- 1 year
- +39.44%
News
newsfilecorp.com BioMark Announces Participation in upcoming MSACL 2026 and BIOHorizon 2026 Life Sciences Conferences The Company will provide an update on the clinical translation of its biomarker platform and showcase industry collaborations supporting scalable, high-throughput mass spectrometry. Vancouver,…
newsfilecorp.com BioMark's Metabolomics Platform Captures Global Scientific Interest Following Publications Demonstrating Superior Diagnostic Performance and Cost Efficiency for Liquid Biopsy Five peer-reviewed studies published in nine months independently confirm high accuracy, robust panel optimization, and commercial viability of BioMark's blood-based assay. Vancouver, British…
newsfilecorp.com BioMark Diagnostics Endorses Global Call for Equitable Access to Early Screening on 2026 World Lung Cancer Day Anchored in the 2026 global campaign's core mission of early detection, equitable access to screening, and compassionate patient support, BioMark advances its multi-marker liquid biopsy to ensure no…
newsfilecorp.com BioMark Diagnostics Secures Landmark Canadian and European Patent Allowances for Early-Stage Lung Cancer Blood Test BioMark prepares to launch its breakthrough liquid biopsy powered by a newly patented algorithm validated in over 15,000 samples across Quebec, France, and Germany. Vancouver, British…
newsfilecorp.com BioMark Secures Broad U.S. Patent for Urine-Based Lung Cancer Screening, Expanding Differentiated Liquid Biopsy Testing Platform New patent expands globally protected IP estate beyond blood into alternative biofluids, positioning the Company's clinical mass spectrometry platform against traditional genomic liquid biopsies.…
newsfilecorp.com BioMark Diagnostics to Present Liquid Biopsy Platform at the Canadian Thoracic Society Research Forum BioMark Comprehensive Metabolomics Assay Selected as Top Canadian Innovation for the CTS Beaver Den Innovation Award Vancouver, British Columbia--(Newsfile Corp. - April 14, 2026) - BioMark…
newsfilecorp.com BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology Advancing Superior Accuracy in Early Lung Cancer Detection Using Selective Metabolic Pathways and Data Enrichment for Enhanced Diagnostic Capabilities Vancouver, British Columbia--(Newsfile Corp. -…
newsfilecorp.com BioMark: 2025 Achievements & 2026 Vision Celebrating A Year of Extraordinary Achievement Vancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the…
newsfilecorp.com BioMark Diagnostics Announces Appointment of Mr. James Lavender to Board of Directors Expanding U.S. market access with an experienced technology investor and AI-driven growth strategist Vancouver, British Columbia--(Newsfile Corp. - December 30, 2025) - BioMark Diagnostics Inc. (CSE:…
newsfilecorp.com BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program Company engages Standards Council of Canada; targets ISO 15189 accreditation for early 2026 Vancouver, British Columbia--(Newsfile Corp. - December 23, 2025) - BioMark Diagnostics Inc. (CSE: BUX)…
newsfilecorp.com BioMark Diagnostics Collaborative Lung Cancer Screening Project Honored by ADRIQ during the 35th Innovation Awards Gala Recognition of BioMark Leadership in Early Cancer Detection Validates Commercialization Trajectory of Multimodal Lung Cancer Screening Platform Vancouver, British Columbia--(Newsfile Corp. - December…
newsfilecorp.com BioMark Aligns with National Strategy to Slash Lung Cancer Mortality with Next-Gen Liquid Biopsy Next-generation metabolomics and AI technology supports the 2026 - 2035 Pan-Canadian Lung Cancer Action Plan's call to expand equitable access to life-saving early diagnosis Vancouver, British…
newsfilecorp.com BioMark's Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening Trial Extensive Validation of BioMark's Comprehensive Metabolic Panel in German 10,000-Participant HANSE Study, within the context of an international consortium supported under the EUREKA Network.…
newsfilecorp.com BioMark Secures Key Patents in Asia's Largest Markets for Early Lung Cancer Liquid Biopsy Pioneering liquid biopsy platform for early lung cancer detection strengthens IP and accelerates commercial strategy in China and Japan diagnostic markets. Vancouver, British Columbia--(Newsfile…
newsfilecorp.com BioMark Diagnostics Establishes African Market Presence Through Strategic Tunisia Healthcare Partnership Proof-of-Concept Trial Opens Door to 90+ Million Population Across North Africa and Francophone Markets Vancouver, British Columbia--(Newsfile Corp. - August 12, 2025) - BioMark Diagnostics Inc.…
newsfilecorp.com BioMark Diagnostics Announces Expansion of Its Specialty Laboratory Services in Quebec to Accommodate Increased Demand from International Partnerships Expansion of BioMark brings advanced equipment and doubles capacity, accelerating commercialization of lung cancer assay Vancouver, British Columbia--(Newsfile Corp. - August 5, 2025) - BioMark…
newsfilecorp.com BioMark Diagnostics Highlights Fiscal Year 2025 Achievements and Sets Bold Strategic Milestones for 2025 - 2026 Vancouver, British Columbia--(Newsfile Corp. - July 30, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy tests…
proactiveinvestors.com BioMark Diagnostics using biomarkers for early cancer detection to save lives, healthcare resources Early detection is critical to improving survival rates and treatment outcomes for cancer patients, but traditional approaches such as mammograms, low-dose CT scans, and biopsies, while effective,…
newsfilecorp.com BioMark Diagnostics Announces Breakthrough Publication Reinforcing Leadership in AI-Powered Metabolomics for Oncology Novel Graph Neural Network (N-GNN) Model Achieves Superior Accuracy in Early Lung Cancer Detection, Paving the Way for Enhanced Diagnostic Capabilities. Vancouver, British Columbia--(Newsfile Corp. -…
newsfilecorp.com BioMark Diagnostics Announces Landmark Publication Validating High Specificity and Accuracy of Its Early-Stage Lung Cancer Test Study Published in a special issue of International Journal of Molecular Sciences Confirms Test's Ability to Distinguish Early Lung Cancer from Other Non-Cancerous Lung Diseases Vancouver, British…